FrontierLab
A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.

Beam Therapeutics Inc. BEAM

Mixed (early) (graded 2026-07-22, not re-checked)   broader-coverage candidate · Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm.

On FrontierLab's discovery record since 2026-07-21 (4 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)

Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-22), not the curated Frontier signal.

Key quality signals

Revenue growth (YoY)158%
Gross margin-39.2%
Gross profits / assets-0.04
Rule of 40-68.6
Net margin-226.6%
Cash runway (months)39.3
PEG
Price / sales17.1

Quality checklist

Fundamentals — snapshot as of 2026-07-22

StageEarly
Share issuance (YoY)17.4% · heavy issuance
Moat
TAM
P/E (trailing)
EPS (trailing)$-0.68
Burn multiple2.3
Gross-margin trend (pts)460.9
Cash / assets0.82
Net debt / EBITDA
Statements as ofQ1 FY2026 · filed 2026-05-07

Momentum context — a snapshot from 2026-07-22, not current

Price at surface$27.29 (as of 2026-07-22)
52-week range$15.6 – $38.26
% off 52-wk high-28.7%
RSI (14)36
Relative volume0.7×

Risk flags

Burning cash — operating margin is negative.Thin gross margin — keeps little of each sales dollar (judge it against its industry).Heavy dilution (~17%/yr) — top-decile share issuers have historically underperformed.

← All broader-coverage names · Curated names → · Open the interactive screener →

Data as of 2026-07-22 (end-of-day). How grades are computed →